Bafna Pharmaceuticals Ltd
Incorporated in 1981, Bafna Pharmaceuticals
Ltd manufactures finished pharmaceutical formulations[1]
- Market Cap ₹ 188 Cr.
- Current Price ₹ 80.0
- High / Low ₹ 113 / 73.2
- Stock P/E
- Book Value ₹ 216
- Dividend Yield 0.00 %
- ROCE -3.00 %
- ROE -5.36 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.37 times its book value
- Debtor days have improved from 151 to 51.8 days.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -15.2% over past five years.
- Company has a low return on equity of -64.3% over last 3 years.
- Working capital days have increased from 49.7 days to 90.4 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|
129 | 175 | 185 | 97 | 85 | 65 | 46 | 44 | 42 | |
110 | 153 | 162 | 114 | 85 | 71 | 81 | 57 | 41 | |
Operating Profit | 19 | 22 | 23 | -18 | 1 | -6 | -35 | -13 | 1 |
OPM % | 15% | 13% | 12% | -18% | 1% | -9% | -77% | -30% | 3% |
1 | 3 | 2 | 43 | 2 | 1 | 31 | 1 | -22 | |
Interest | 8 | 12 | 13 | 13 | 13 | 11 | 7 | 2 | 0 |
Depreciation | 6 | 8 | 9 | 6 | 5 | 4 | 4 | 3 | 3 |
Profit before tax | 5 | 5 | 2 | 6 | -15 | -20 | -15 | -17 | -24 |
Tax % | 64% | 27% | 42% | -2% | -1% | -4% | 15% | 6% | 0% |
2 | 4 | 1 | 6 | -15 | -19 | -17 | -18 | -24 | |
EPS in Rs | 1.00 | 2.12 | 0.75 | 3.31 | -7.52 | -10.23 | -7.08 | -7.98 | -104.54 |
Dividend Payout % | 0% | 28% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -15% |
3 Years: | -13% |
TTM: | -3% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 24% |
TTM: | 90% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | % |
3 Years: | -14% |
1 Year: | -9% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -46% |
3 Years: | -64% |
Last Year: | -5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 18 | 19 | 19 | 19 | 19 | 19 | 24 | 24 | 2 |
Reserves | 40 | 46 | 50 | 53 | 39 | 20 | 14 | -5 | 49 |
85 | 100 | 108 | 69 | 80 | 82 | 47 | 46 | 3 | |
76 | 96 | 59 | 59 | 54 | 57 | 54 | 54 | 17 | |
Total Liabilities | 219 | 261 | 236 | 200 | 193 | 178 | 138 | 119 | 71 |
76 | 73 | 69 | 55 | 53 | 49 | 45 | 37 | 35 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 17 | 17 | 17 | 0 | 0 | 0 |
143 | 188 | 167 | 128 | 123 | 113 | 93 | 82 | 36 | |
Total Assets | 219 | 261 | 236 | 200 | 193 | 178 | 138 | 119 | 71 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|
29 | 37 | 2 | 11 | 1 | -1 | -7 | -2 | -34 | |
-38 | -6 | -7 | 60 | -0 | -5 | 38 | 15 | 33 | |
-1 | -12 | -13 | -71 | -1 | 6 | -31 | -14 | 7 | |
Net Cash Flow | -9 | 19 | -18 | -0 | -0 | -0 | 0 | -0 | 6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 237 | 191 | 193 | 335 | 292 | 303 | 195 | 208 | 52 |
Inventory Days | 93 | 63 | 77 | 72 | 90 | 118 | 102 | 122 | 208 |
Days Payable | 227 | 223 | 118 | 189 | 208 | 168 | 273 | 519 | 229 |
Cash Conversion Cycle | 103 | 30 | 152 | 218 | 174 | 253 | 24 | -190 | 31 |
Working Capital Days | 202 | 151 | 204 | 265 | 300 | 205 | 74 | -15 | 90 |
ROCE % | 11% | 9% | -12% | -2% | -7% | -37% | -22% | -3% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2024 published in "Business Standard" and …
- Unaudited Financial Results For The Quarter Ended 30.09.2024 11 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 11/11/2024
11 Nov - Board approved unaudited financial results for Q2 2024.
-
Update on board meeting
4 Nov - Board meeting to approve Q2 financial results.
-
Board Meeting Intimation for Board Meeting Scheduled On November 11, 2024
4 Nov - Board meeting to approve Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Profile:[1][2][3]
Company is manufacturing over 336
licensed pharmaceutical formulations
and has globally registered 78 of its
products viz. Afenac-p Tab, Afenac-th
Tab, finished solid oral and liquid oral
dosage forms of Betalactam and Non – Betalactam and Cephalosporin products